BamSEC and AlphaSense Join Forces
Learn More

CARGO Therapeutics Inc.

NASDAQ: CRGX    
Share price (12/24/24): $14.66    
Market cap (12/24/24): $675 million

Material Contracts Filter

EX-10.2
from 10-Q 5 pages This Corporate Bonus Plan (The “Plan”) Is Intended to Provide an Incentive for Achievement of Annual Corporate and/or Individual Goals and to Motivate Eligible Executives and Employees of CARGO Therapeutics, Inc. (The “Company”) and Its Subsidiaries to Tie Their Goals and Interests to Those of the Company and Its Stockholders, Reward Employees for Achievement of Corporate and Individual Goals, and to Enable the Company to Attract and Retain Employees. the Plan Is Effective as of January 1, 2024 (The “Effective Date”) and Shall Govern Bonuses Awarded for the Annual Performance Period Commencing January 1, 2024 and Consecutive Annual Performance Periods Thereafter (Each of Calendar Year 2024 and Such Consecutive Annual Performance Periods, a “Performance Period”). Employees Are Eligible to Participate in Only One Company Bonus Plan at Any Given Time, and Concurrent Participation in Multiple Bonus Plans, if Any, Is Not Permitted. 2. Eligible Employees
12/34/56
EX-10.1
from 10-Q 6 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Is Treated by the Registrant as Private or Confidential. First Amendment to Lease
12/34/56
EX-10.3
from 10-Q 4 pages CARGO Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Program
12/34/56
EX-10.2
from 10-Q 4 pages Second Amendment to Sublease
12/34/56
EX-10.1
from 8-K 19 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Is Treated by the Registrant as Private or Confidential. Sublease Agreement
12/34/56
EX-10.1
from 8-K 37 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 10-Q 27 pages Exchange Agreement
12/34/56
EX-10.1
from 10-Q 4 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Is Treated by the Registrant as Private or Confidential
12/34/56
EX-10.1
from 10-K 54 pages Lease Agreement
12/34/56
EX-10.1
from 10-Q 54 pages Lease Agreement
12/34/56
EX-10.14
from S-1/A 3 pages CARGO Therapeutics, Inc. Non-Employee Director Compensation Program
12/34/56
EX-10.13
from S-1/A 18 pages September 22, 2023 Offer Letter Ginna Laport [****] Dear Ginna: On Behalf of CARGO Therapeutics, Inc, a Delaware Corporation (The “Company”), I Am Pleased to Offer You Employment With the Company. the Purpose of This Letter (The “Agreement’’) Is to Summarize the Terms of Your Employment With the Company, Should You Accept Our Offer
12/34/56
EX-10.12(B)
from S-1/A 7 pages First Amendment to Sublease
12/34/56
EX-10.12(A)
from S-1/A 131 pages Material contract
12/34/56
EX-10.11
from S-1/A 17 pages Form of Indemnification and Advancement Agreement
12/34/56
EX-10.10
from S-1/A 16 pages Shishir Gadam [***] Dear Shishir: On Behalf of Syncopation Life Sciences, Inc., a Delaware Corporation (The “Company”), I Am Pleased to Offer You Employment With the Company. the Purpose of This Letter (The “Agreement”) Is to Summarize the Terms of Your Employment With the Company, Should You Accept Our Offer: 1. Position and Duties. (A). Position and Term. You Will Be Employed to Serve on a Full-Time Basis as Chief Technology Officer of the Company (Cto), Effective as of 17 January 2022 or Any Other Date Mutually Agreed Upon Between You and the Company (The “Effective Date”)
12/34/56
EX-10.9
from S-1/A 16 pages Material contract
12/34/56
EX-10.8
from S-1/A 17 pages Gina Chapman [***] Dear Gina: On Behalf of Syncopation Life Sciences, Inc., a Delaware Corporation (The “Company”), I Am Pleased to Offer You Employment With the Company. the Purpose of This Letter (The “Agreement”) Is to Summarize the Terms of Your Employment With the Company, Should You Accept Our Offer: 1. Position and Duties (A) Position and Term. You Will Be Employed to Serve on a Full-Time Basis as Chief Executive Officer of the Company (CEO), Effective as of May 2nd, 2022 (The “Effective Date”). (B) Duties and Responsibilities. as CEO, You Will Have the Duties, Responsibility, and Authority Customary for Such Position and Such Other Duties as Reasonably Assigned by the Board. 2. Compensation and Related Matters
12/34/56
EX-10.7
from S-1/A 16 pages CARGO Therapeutics, Inc. 2023 Employee Stock Purchase Plan Article 1 Purpose
12/34/56
EX-10.6(C)
from S-1/A 7 pages CARGO Therapeutics, Inc. 2023 Incentive Award Plan Restricted Stock Unit Award Grant Notice
12/34/56